Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Caitlin E. Cox

May 15, 2020

News Features

Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance

Shelley Wood

April 29, 2020

News Features

The Mystery of the Missing STEMIs During the COVID-19 Pandemic

Shelley Wood

April 02, 2020

News Daily News

Cancelled Cath Lab Activations and Timely Reperfusion: A ‘Balancing Act’

Michael O'Riordan

August 21, 2018

$A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years$

News Daily News

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

Yael L. Maxwell

August 10, 2018

$Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It$

News Conference News SCAI 2017

Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It

L.A. McKeown

May 19, 2017

News Daily News

STEMI Patients Far From PCI Centers Fare Well With Pharmacoinvasive Strategy

L.A. McKeown

October 05, 2016

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

News Daily News

Subestudio del Ensayo STREAM: El Fracaso de los Agentes Líticos Equivale a Peores Resultados en Pacientes STEMI sometidos a Terapia Fármacoinvasiva

July 17, 2014

News Daily News

STREAM分项研究：细胞溶解失败将给接受药物介入治疗的STEMI患者带来更差的结果

July 17, 2014

News Daily News

STREAM Substudy: Lytic Failure Means Worse Outcomes for Pharmacoinvasively Treated STEMI Patients

July 17, 2014

Advertisement

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Women Stand to Gain the Most From Standardized STEMI Protocols

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance

The Mystery of the Missing STEMIs During the COVID-19 Pandemic

Cancelled Cath Lab Activations and Timely Reperfusion: A ‘Balancing Act’

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It

STEMI Patients Far From PCI Centers Fare Well With Pharmacoinvasive Strategy

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Subestudio del Ensayo STREAM: El Fracaso de los Agentes Líticos Equivale a Peores Resultados en Pacientes STEMI sometidos a Terapia Fármacoinvasiva

STREAM分项研究：细胞溶解失败将给接受药物介入治疗的STEMI患者带来更差的结果

STREAM Substudy: Lytic Failure Means Worse Outcomes for Pharmacoinvasively Treated STEMI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content